Advertisement
A vs COO
Which Stock Would AI Choose? Agilent Technologies (A) vs. The Cooper Companies (COO) Stock Comparison
Key Takeaways
- Agilent Technologies (A) delivered a strong fiscal Q2 2026 earnings beat with 10% revenue growth and raised full-year guidance, driving positive stock momentum in recent weeks.
- The Cooper Companies (COO) reported solid Q1 2026 results with 6% revenue growth and 20% non-GAAP EPS increase, though its stock has faced pressure and underperformed year-to-date.
- A operates in life sciences and diagnostics tools, while COO focuses on contact lenses and surgical products, exposing the companies to different healthcare sub-sectors and growth drivers.
- Recent market activity shows A benefiting from broad-based demand across end markets, contrasting with COO’s more modest organic growth amid competitive pressures in medical devices.
- Both companies operate in the healthcare sector with exposure to recurring revenue streams, but A’s latest results highlight stronger near-term momentum compared to COO’s steadier but less reactive profile.
- Relative performance in recent market activity favors A following its earnings catalyst, while COO’s valuation metrics suggest potential for recovery ahead of its upcoming quarterly update.
Introduction
This comparison examines Agilent Technologies (A) and The Cooper Companies (COO), two healthcare-focused stocks with distinct business models within the medical and life sciences space. Investors and traders seeking to understand relative performance, sector positioning, and recent momentum between a diagnostics and research tools provider and a medical devices specialist may find this analysis relevant. The discussion draws on verifiable developments from recent market activity to highlight contrasts in earnings execution, growth trajectories, and market sentiment without offering forward-looking predictions.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies (A) provides analytical instruments, reagents, and services primarily for life sciences, diagnostics, and applied markets. In recent market activity, the company reported fiscal second-quarter 2026 results that exceeded expectations across revenue and earnings metrics. Revenue reached $1.83 billion, reflecting 10% year-over-year growth and 6.3% core growth, with strength in pharmaceutical, chemical, and advanced materials segments. Non-GAAP earnings per share came in at $1.49, up 14% from the prior year, accompanied by margin expansion. Management raised full-year revenue and earnings guidance, citing broad demand and operational improvements. These results contributed to positive sentiment and upward price movement in the stock during the period following the release.
The Cooper Companies (COO) Overview and Recent Performance
The Cooper Companies (COO) develops and manufactures contact lenses through its CooperVision segment and surgical and fertility products via CooperSurgical. In recent market activity, the company posted first-quarter 2026 results showing revenue of $1.024 billion, up 6% year-over-year or 3% organically. GAAP diluted earnings per share rose 27% to $0.66, while non-GAAP diluted earnings per share increased 20% to $1.10. The firm continued share repurchases during the quarter. Despite the earnings delivery, the stock has experienced downward pressure year-to-date amid broader sector dynamics and modest organic growth rates. Attention remains on the upcoming second-quarter update scheduled for early June as a potential near-term catalyst.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of high-performing AI trading bots from a platform that offers hundreds of such bots trading thousands of different tickers. Only the best and most suitable bots for prevailing market conditions earn placement in this section. Available bots exhibit varied trading styles, strategies, timeframes, performance statistics, and ticker sets, with many demonstrating win rates in ranges such as 60-80% and profit factors above 1.5 across different market environments. This resource allows users to explore data-driven approaches tailored to specific assets and conditions. Explore the full selection on the Trending AI Robots page for additional details.
Head-to-Head Comparison
Agilent Technologies (A) and The Cooper Companies (COO) operate in adjacent yet differentiated areas of healthcare. A’s business model centers on high-margin analytical instruments and recurring consumables for research and diagnostics, providing exposure to pharmaceutical and industrial R&D spending. COO’s model emphasizes consumer and surgical medical devices, with significant recurring revenue from contact lenses and procedure-related products. Recent momentum has favored A following its broad-based earnings beat and guidance lift, whereas COO has shown steadier but lower organic growth and faced share price weakness. Risk factors for A include sensitivity to capital spending cycles in life sciences, while COO contends with competition in vision care and potential reimbursement or regulatory shifts in surgical segments. Market sentiment in recent activity reflects greater near-term optimism around A’s execution compared to COO’s more measured outlook ahead of its next earnings release. Trade-offs include A’s potentially higher volatility tied to earnings surprises versus COO’s defensive characteristics in essential medical products.
Tickeron AI Verdict
Based on observable factors such as recent earnings consistency, margin trends, and positive market reaction to catalysts, Tickeron’s AI would currently assign a higher probabilistic weighting to Agilent Technologies (A) over The Cooper Companies (COO). A’s demonstrated ability to exceed expectations across multiple segments and raise guidance provides a clearer signal of near-term stability and positioning relative to COO’s solid but less momentum-driven profile. This assessment remains probabilistic and tied to verifiable recent data rather than definitive forecasts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and COO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileCOO’s FA Score has 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- COO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while COO’s TA Score has 5 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 5 bearish.
- COO’s TA Score: 5 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а -3.14% price change this week, while COO (@Pharmaceuticals: Other) price change was -3.45% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.04%. For the same industry, the average monthly price growth was +3.10%, and the average quarterly price growth was -2.79%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.77%. For the same industry, the average monthly price growth was -0.42%, and the average quarterly price growth was -14.37%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
COO is expected to report earnings on Sep 02, 2026.
Industries' Descriptions
@Medical Specialties (+1.04% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-1.77% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| A | COO | A / COO | |
| Capitalization | 35.7B | 12.8B | 279% |
| EBITDA | 1.96B | 1.08B | 181% |
| Gain YTD | -6.662 | -20.181 | 33% |
| P/E Ratio | 25.40 | 55.44 | 46% |
| Revenue | 7.23B | 4.15B | 174% |
| Total Cash | 1.81B | 125M | 1,446% |
| Total Debt | 3.36B | 2.5B | 134% |
A | COO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 91 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 44 | 86 | |
PRICE GROWTH RATING 1..100 | 47 | 59 | |
P/E GROWTH RATING 1..100 | 62 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 46 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (6) in the Biotechnology industry is significantly better than the same rating for COO (72) in the Medical Specialties industry. This means that A’s stock grew significantly faster than COO’s over the last 12 months.
A's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as COO (100) in the Medical Specialties industry. This means that A’s stock grew similarly to COO’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for COO (86) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than COO’s over the last 12 months.
A's Price Growth Rating (47) in the Biotechnology industry is in the same range as COO (59) in the Medical Specialties industry. This means that A’s stock grew similarly to COO’s over the last 12 months.
COO's P/E Growth Rating (14) in the Medical Specialties industry is somewhat better than the same rating for A (62) in the Biotechnology industry. This means that COO’s stock grew somewhat faster than A’s over the last 12 months.
| A | COO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | 2 days ago 60% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 55% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 62% |
| MACD ODDS (%) | 2 days ago 59% | N/A |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 60% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 49% |
| Advances ODDS (%) | 9 days ago 60% | 19 days ago 57% |
| Declines ODDS (%) | 7 days ago 62% | 8 days ago 60% |
| BollingerBands ODDS (%) | 2 days ago 52% | 2 days ago 65% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 50% |
Advertisement
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with TMO. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then TMO could also see price increases.
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with BDX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then BDX could also see price increases.